ProCE Banner Activity

Expert Guidance on the Expanding Role of Immunotherapy in HNSCC: Downloadable Slides

Slideset Download
Download expert recommendations on the management of patients with head and neck cancer in this slideset from the HNSCC live meeting program.

Released: January 07, 2020

Expiration: January 05, 2021

No longer available for credit.

Share

Faculty

Barbara Burtness

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine
Yale School of Medicine
Chief Translational Research Officer
Division Chief
Head and Neck/Sarcoma Oncology
Co-leader
Developmental Therapeutics Program
Director
Yale Head and Neck SPORE
Yale Cancer Center
Chair
ECOG-ACRIN Cancer Research Group
New Haven, Connecticut

Cristina P. Rodriguez

Cristina P. Rodriguez, MD

Associate Professor
Department of Medicine
University of Washington
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine
Yale School of Medicine
Chief Translational Research Officer
Division Chief
Head and Neck/Sarcoma Oncology
Co-leader
Developmental Therapeutics Program
Director
Yale Head and Neck SPORE
Yale Cancer Center
Chair
ECOG-ACRIN Cancer Research Group
New Haven, Connecticut

Barbara Burtness, MD, has disclosed that she has received funds for research support from Advaxis, Bristol-Myers Squibb, Cue Biopharma, Formation Biosciences, GlaxoSmithKline, and Merck; consulting fees from Aduro, Alligator Biosciences, ALX Oncology, AstraZeneca, Celgene, Cue Biopharma, GlaxoSmithKline, Maverick, Merck, Nanobiotix, and MedImmune; and other financial or material support from Merck.

Cristina P. Rodriguez, MD

Associate Professor
Department of Medicine
University of Washington
Seattle, Washington

Cristina P. Rodriguez, MD, has disclosed that she has received consulting fees from Cue Biopharma and funds for research support paid to her institution from AstraZeneca, Ayala, and Bristol-Myers Squibb and that her spouse has received consulting fees from AstraZeneca and Merck and funds for research support paid to his institution from Acerta, AstraZeneca, Genentech, Incyte, Merck, Pharmacyclics, Portola, and Seattle Genetics.